All In Biotech

NDA 214919 · Fresenius Kabi USA

Glycopyrrolate

Glycopyrrolate · Intramuscular, Intravenous

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 21, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

230

60 Phase 3, 12 recruiting

FAERS reports

5,527

4,660 serious, 660 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 14, 2024.

Glycopyrrolate Injection, USP (0.2 mg/mL) is an anticholinergic indicated for use in: anesthesia (all ages) for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation, intraoperatively to counteract surgically or drug-induced or vagal reflex-associated arrhythmias, and for protection against peripheral muscarinic effects of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing agents. peptic ulcer (adults) as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. Glycopyrrolate Injection is an anticholinergic indicated: in anesthesia (adult and pediatric patients) for reduction of airway or gastric secretions, and volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation, intraoperatively to counteract surgically or drug-induced or vagal reflex-associated arrhythmias, and for protection against peripheral muscarinic effects of cholinergic agents. ( 1 ) in peptic ulcer (adults) as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or oral medication is not tolerated.

Mechanism: Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 16, 2025 Supplement 2 · Efficacy LetterLabel
  • Apr 21, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • GLYCOPYRROLATE · GLYCOPYRROLATE 0.6MG/3ML (0.2MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycopyrrolate" as an intervention, any sponsor and status, largest first.

All 230 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,054
  • asthma852
  • wheezing719
  • cough669
  • pneumonia576
  • drug ineffective444
  • off label use374
  • fatigue373
  • malaise365
  • chronic obstructive pulmonary disease361
  • productive cough350
  • chest discomfort337

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200514
200616
200730
200829
200946
201062
201174
201288
201370
2014125
2015134
2016216
2017428
2018291
2019315
2020281
2021444
2022619
2023568
2024605
2025669
2026390

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Glycopyrrolate* (Glycopyrrolate)

2024 spending

$10.2M

Beneficiaries

55,299

244,563 claims

Per beneficiary

$184

$0.45 per unit

View as table
YearSpending
2020$10,018,426
2021$8,357,338
2022$9,557,835
2023$11,614,817
2024$10,187,211

Part B: Glycopyrrolate* (Glycopyrrolate*) · HCPCS J1596

2024 spending

$485

Beneficiaries

91

95 claims

Per beneficiary

$5

2024 ASP limit $0.52 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$485

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 443 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.